

Difference Expression of M6A Regulators in Breast Cancer and its Relationship with Immune Response

Ozlem Roring*

Department of Internal Medicine, Radboud University Medical Center, Nijmegen, The Netherlands

ABSTRACT

Objective: RNA N6-methyl adenosine (M6A) plays a key role in tumor development. However, its role in breast cancer has not been fully elucidated.

Materials and Methods: In this study, 23 M6A RNA regulatory factors were systematically analyzed from the Tumor Cancer Genome Atlas Program (TCGA) database to analyze the relationship between M6A and breast cancer by bioinformatics. Then, We further detected the expression of M6A by immunohistochemical method, and analyzed the relationship between it and the prognosis of breast cancer.

Results: We found increased expression of 6 regulators in breast cancer patients. We further studied the effect of abnormal expression of CBLL1, YTHDC1, METTL14, HNRNPA2B1, RBMX, and HNRNPC on the survival time of breast cancer. In addition, we also found that the abnormality of the M6A regulatory factor is closely related to immune infiltration and genetic changes.

Conclusion: Our findings suggest that the expression of M6A regulators in breast cancer has important clinical diagnostic significance and that abnormal expression may be associated with poor clinical prognosis in Breast Cancer (BC). This helps to provide us with a new direction of targeted therapy for breast cancer.

Keywords: M6A, RNA Methylation, Breast Cancer, TCGA, Immune Infiltration

INTRODUCTION

According to the latest report of the World Health Organization, the incidence of breast cancer is increasing year by year. And the incidence of breast cancer has surpassed that of lung cancer and has become the highest incidence of malignant tumors, accounting for 24.5% of female malignant tumors. It has become the highest and most common carcinoma among women [1,2]. Breast Cancer (BRC) is also the leading cause of cancer-related death for women in the vast majority of countries [3]. Despite significant advances in treatment in recent years, the prognosis for breast cancer remains poor. Therefore, further research is needed to determine the underlying mechanism of breast cancer occurrence and development.

Epigenetic irregularity is a consistent feature of many cancers [4]. In addition to well-known classical epigenetic regulatory mechanisms such as chromatin remodelling, Deoxyribonucleic Acid (DNA) methylation, and histone modification, Ribonucleic Acid (RNA) N6-methyl Adenosine (M6A) is also considered as a new epigenetic regulator, and has been considered one of the newest research projects in the epigenetic area [5]. RNA N6-methyladenosine (M6A) which happens at the N6 position of adenosine, is an internal modification prevalent in mammalian mRNA and noncoding RNAs, and it plays the ubiquitous role of "writer", "eraser" and "reader" in RNA processing and it influences mRNA splicing, export, localization, translation, decay, and stability [6,7]. The writer complex contains the Methyl Transferase METTL3 and METTL14, the METTL3 adaptor Wilms Tumor 1-Associating Protein (WTAP), and other related proteins, including KIAA1429, RBM15/15B, and ZC3H13 [8]. In the METTL3-METTL14 methyltransferase domain complex, METTL3 acts as the catalytic subunit, whereas METTL14 provides an RNA-binding scaffold that activates and enhances the catalytic activity of METTL3 [9]. WTAP is catalytically inactive but can interact with METTL3 and METTL14 to regulate the M6A level of RNA transcription [10]. Two different enzymes are known to be involved in the M6A elimination process: Fat Mass and Obesity (FTO) and ALKBH5 [11]. However, it was found that FTO preferentially demethylates M6A, an M6A-related nucleoside

Correspondence to: Otem Roring, Department of Internal Medicine, Radboud University Medical Center, Nijmegen, The Netherlands, E-mail: otemrori -ng@gmail.com

Received: 11-Sep-2023, Manuscript No. RDT-22-22903; Editor assigned: 14-Sep-2023, PreQC No. RDT-22-22903 (PQ); Reviewed: 28-Sep-2023, PreQC No. RDT-22-22903; Revised: 05-Oct-2023, Manuscript No. RDT-22-22903 (R); Published: 12-Oct-2023, DOI: 10.35248/2329-6682.23.12.241.

Citation: Roring O (2023) Difference Expression of M6A Regulators in Breast Cancer and its Relationship with Immune Response. Gene Technol. 12:241 Copyright: © 2023 Roring O. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. that is present in mRNA in high abundance [12]. ALKBH5 has been found to be a major M6A demethylase [13]. A growing body of evidence suggested that M6A regulates gene expression and plays a vital part in cancer through a variety of mechanisms. New evidence showed that M6A modification is associated with tumor proliferation, glycolysis, apoptosis, and metastasis [14]. Abnormal expression of M6A methylation regulatory factors can also lead to cancer. However, M6A modification can play both carcinogenic and anticancer roles in malignant tumors. Such as ALKBH5 and METTL3 play a distinct role in different tumor types [15-17]. M6A regulators performed variant functions to different tumor types showing that the regulation of M6A methylation modification levels is absolutely complex. Found by reading relevant literature, M6A plays a significant role in the tumor immune microenvironment, which in turn affects the occurrence, development and treatment sensitivity of tumors [18-24]. A study has shown that key functions in regulatory T cells have a clear M6A mRNA dependence, making them potentially important targets in anti-tumor immunotherapy [25-29]. More and more studies have shown that M6A is associated with the development of breast cancer (Table 1). Closely related to the exhibition. M6A regulatory protein is heavy in the development of cancer [30-33]. To adjust factor, its level of expression is often directly determines the swollen tumor pathological process [34]. Although the evidence revealed M6A RNA methylation involved in the onset and development of cancers, the specific role of M6A in breast cancer has not been fully demonstrated [35].

Therefore, we systematically analyzed 23 M6A methylation regulators and examined their expression of them in breast cancers and normal controls based on open biological data. This study used the data in the Tumor Genome Atlas (TCGA) database to analyze the expression of M6A methylation regulator in breast cancer and its relationship with clinicopathological characteristics and we also used bioinformatics methods to predict the potential functions of these M6A regulators. Finally, we analyzed the critical M6A methylation regulators and uncovered the M6A-related biological mechanism in breast cancer.

Tab	le 1	:1	List	of	the	expression	and	function	of	M	Aregu	latory	proteins	in	breast	cancer.
-----	------	----	------	----	-----	------------	-----	----------	----	---	-------	--------	----------	----	--------	---------

M6Aregulators	M6AModification type	Expression trend	Target gene	Function	Reference
METTL3	writer	1	HBXIP	Promote cell proliferation	
		\downarrow	Bcl-2	Inhibition of apoptosis	18
METTL14	writer	1	has-miR-146a-5p	Promote cell proliferation, migration and invasion, promote cell colony formation, promote cell cycle	19,20
		\downarrow	CXCR4 CYP1B1	Inhibit clonogenesis and cell viability	
WTAP	writer	\downarrow	-		20
VIRMA/KIAA1429	writer	1	CDK1	Promote cell proliferation and metastasis	21
RBM15	writer	\uparrow			
RBM15B	writer	↑ (-	•	22
CBLL1	writer		ERa	Inhibit cell proliferation and migration	23
FTO	eraser	1	BNIP	Promote cell proliferation and metastasis, promote cell clonal formation	24,25
			PI3K/AKT	ability, increase ATP production, promote glycolysis and lactic acid formation	24
ALKBH5	eraser	Т	NANOG	Promote cell viability, clone formation and metastasis	26
IGF2BP1/IMP1	reader	↑	UCA1	Promote cell proliferation, reduce invasion and metastasis	
		\downarrow	c - MYC IGF - II	Inhibition of tumor growth	27
IGF2BP2/IMP2	reader	\uparrow	PR		
			RPSAP52	Promote migration, migration and growth, promote self - renewal	28
IGF2BP3/IMP3	reader	\uparrow	WNT5B		
			BCRP	Promote cell proliferation, invasion and metastasis, promote cell drug	
			CD44	resistance, promote the stem - like properties	29
			CERS6		
EIF3H	reader	↑	YAP	Promote cell migration and metastasis	30
HNRNPC	reader	1		Promote cell proliferation	31
HNRNPA2B1	reader	↑	STAT3 EKR1/2	Promote cell proliferation and reduce cell apoptosis	
		Ļ	ERK - MAPK/ Twist GR-beta/ TCF4 PFN2	Inhibit cell metastasis	32,33
YTHDF1	readers	1	elF3C	The translation efficiency of mRNA modified with M6Amethylation was improved	34

MATERIALS AND METHODS

Data source

Public gene expression data, copy number variation data, RNA methylation data, and clinical annotations were collected from Tumor Cancer Genome Atlas (TCGA) database, the Gene-Expression Omnibus (GEO), and the International Cancer Genome Consortium (ICGC). Including 1099 cancer samples and 114 normal samples.

Exclusion criteria:

- There is no complete RNA sequencing data in the sample;
- The sample is not before treatment;
- Advanced breast cancer.

Finally, 1092 cases of breast cancer and 113 cases of normal breast tissue were included.

Selection and differential expression analysis of M6A methylation regulators

According to the related literature [36-37], we selected 23 M6A methylation regulators that regulate RNA methylation, including 10 writers, and 2 erasers, 11 readers. The differential expression analysis of 23 M6A regulators in breast cancers and normal controls was compared by the "limma" package in R, a heatmap was assessed by the "Complex Heatmap" package.

Expression analysis

We used UALCAN to confirm the correlation between M6A regulators and clinical parameters in breast cancer [38].

Gene alteration analysis of M6A regulator in breast cancer

CBioPortal is an open-access website to explore, visualize and analyze multidimensional cancer genomics data. We used this website to analyze the genetic alterations of M6A regulators in breast cancer.

Immune response analysis

The correspondence of M6A regulators with levels of immune cell infiltration and Immune infiltration score were detected. Immune infiltrating cells16 include are aDC (activated DC); B cells; CD8 T cells; Cytotoxic cells; DC; Eosinophils; iDC (immature DC); Macrophages; Mast cells; Neutrophils; NK CD56bright cells; NK CD56dim cells; NK cells; pDC (Plasmacytoid DC); T cells; T helper cells; Tcm (T central memory); Tem (T effector memory); Tfh (T follicular helper); Tgd (T gamma delta); Th1 cells; Th17 cells; Th2 cells; Treg. Immune infiltration score [39], include: stromal score, estimate score, immune score. Then, we assessed the correlations between the expression of M6A regulators and Immuno regulators (including Immuno inhibitors, Immuno stimulator, and MHC molecules) by using *TISIDB* database.

Survival analysis

GCSALite mRNA expression module calculates the genomic differential expression between different cancers according to TCGA expression data. The results of module analysis provide differential expression, survival analysis, and subtype analysis [40]. For expression survival analysis, we use 33 cancer types of clinical

tumor data, some uncensored data was left out. Merging mRNA expression and clinical survival data by sample barcode, we use median RSEM value to divide tumor samples into high and low groups. Then, we use the R package survival to fit survival time and survival status with two groups. We calculate the Cox Proportional-Hazards model for every gene and draw Kaplan-Meier curves with log-rank tests for every single gene. The genes with Kaplan-Meier log-rank test p-value less than 0.05 would be retained and gathered into the final figure.

The correlation between survival time and expression of M6A regulators in breast cancer was measured by using the K-M map and determined by the endpoint reported before.

GO and KEGG analysis

Using the Database for Annotation, Visualization and Integrated Discovery (DAVID), we performed Gene Ontology (GO) and Kyoto Encyclopaedia of Genes and Genomes (KEGG) pathway enrichment analysis based on CO expressed genes. Select the critical value p<0.05 as the critical value.

Statistical analysis

All statistical analyses were performed using R software (version 4.0.5). The Wilcoxon's test was applied to contrast the expression of M6A regulators between cancer and normal tissues. Lasso regression was performed by the "glmnet" package in R. The chi-square test was used to compare the relationship between M6A and Immune Response. The validation of the diagnostic models was assessed by the receiver operating characteristic (ROC) curve. For all the analyses, a P-value less than 0.05 were regarded as statistically significant.

RESULTS

M6A regulator mutations have been linked to human cancer survival

To assess the functional role of the M6A regulators in human cancers, we used the GCSALite mRNA expression module based on the TCGA expression data to analyze the association between Abnormalities of different types of M6A regulators and survival time and survival status in human cancers. As shown in Figure 1, the dot represents the gene that affects the survival of the cancer types; the p-value is the Kaplan Meier P-value. The dot colour indicates the worse of the high or low expression in the cancer types. The larger the dot, the greater the genetic influence. The results show that the types of genes that influence cancer survival and their expression vary from tumor to tumor. For example, there were eight genes affecting the survival of breast cancer patients, among which 4 genes such as IGF2BP1, KIAA1429, FTO, YTHDF3, METTL16, and YTHDF1 were highly expressed and 2 genes such as HNRNPC and RBM15B were low expressed. And we can find that RBM15B had a significant effect Figure 1.

The aberrations of M6A regulators were correlated to prognosis in breast cancer

The study focused on exploring the role of M6A in the prognosis of breast cancer patients. According to whether M6A methylation was performed, the patients were divided into altered group and unaltered group. The Altered group (n=1136) and Unaltered group (n=1933) the Altered group (n=742), and the Unaltered

group (n=1336) were included in the TCGA-BRCA database. After comparison, we could conclude that the altered group was remarkably correlated to a worse prognosis. In other words, the altered group had a shorter OS time and was more prone to relapse. According to the results of Figure 1, we know that the expression of M6A regulators is different in breast cancer, but as shown in Figure 2, the occurrence of M6A methylation is associated with poor prognosis of breast cancer.



Figure 1: Analysis of association between Abnormalities of different types of M6A regulators and survival time and survival status in human cancers, where the dot represents the gene that affects the survival of the cancer types, the p-value is the Kaplan Meier P-value. Note: (\bullet) H; (\bullet) L; (\bullet) 2.5; (\bullet) 5.0; (\bullet) 7.5; (\bullet) 10.0; (\bullet) 12.5.



Figure 2: The Aberrations of m6A regulators were correlated to prognosis in breast cancer. **Note:** (A)Overall survival; p-value: 1.106e-4; (B)Relapse free; p-value: 6.72e-9; (**■**) Altered group; (**■**) Unaltered group.

Amplification, deletion, and mutation of M6A regulators in breast cancer

In this study, we were queried 6110 patients/6437 samples in 8 studies to explore genetic changes. As present in Figure 3, we found varying degrees of genetic change in 23 M6A regulators, including, METTL3, METTL14, WTAP, ZC3H13, RBM15, RBM15B, VIRMA, METTL16, FTO, ALKBH5, YTHDC1, YTHDC2, YTHDF1, YTHDF2, YTHDF3, HNRNPA2B1, IGF2BP1, IGF2BP2, IGF2BP3, RBMX, HNRNPC, ZCCHC4, CBLL1. We revealed most of the M6A regulators were amplified, deleted, mutated in BRCA, among which VIRMA displayed the highest incidence rate (17%). We can also find that VIRMA is prone to Amplification, followed by

YTHDF3. FTO is prone to Deep deletion Figure 3.



Figure 3: Amplification, deletion, and mutation of M6A regulators in breast cancer. Querying 6110 patients/6437 samples in 8 studies. Note:
(1) Inframe Mutation (unknown significance); (1) Missense mutation (unknown significance); (1) Splice Mutation (unknown significance); (1) Amplification; (1) Deep Deletion; (1) No alterations-Not profiled; (11) Truncating Mutation (unknown significance).

Expression profile of M6A regulators in breast cancer

The level of M6A regulators in TCGA was presented in Figure 4. We compared the expression of 23 M6A regulators in cancer and normal tissues. There was significant differential expression of 14 genes showed in the heat map (Figure 4A), vio-plot revealed the same result (Figure 4B). The M6A regulators include Writer: METTL14, METTL16, WTAP, VIRMA, KIAA1429, ZC3H13, RBM15; Erasers: FTO; Readers: YTHDC1, YTHDF1, HNRNPA2B1, HNRNPC, IGF2BP1, IGF2BP2, IGF2BP3, ZCCHC4. Among them, VIRMA/ KIAA1429, YTHDF1, HNRNPA2B1, HNRNPC, IGF2BP1, and IGF2BP3 were significantly up-regulated in breast cancer tissues. However, the expression of METTLE14, METTL16, WTAP, FTO, ZC3H13, YTHDC1, IGF2BP3 and ZCCHC4 was reduced to varying degrees compared with normal samples. Meanwhile, there was no difference in METTL3, ALKBH5, RBM15, RBM15B, YTHDF2, YTHDF3, YTHDC2, RBMX, CBLL1 expression between normal and tumor samples (Figure 4).



Figure 4: (A)Expression Profile of M6A Regulators in Breast Cancer; (B) The expression levels of 6 M6A regulators showed increased expression in EC samples, and 8 regulators showed reduced expression. **Note:** (**■**) Normal; (**■**) Tumour. p<0.05; "p<0.01; ""p<0.001.

Correlation of dysregulating M6A with shorter OS times in breast cancer patients

In this study, we used the k-M curve to detect the role of each M6A regulator in the prognosis of breast cancer patients. (Figures 5A-5F) We found that high CBLL1 (Figure 5A), HNRNPA2B1 (Figure 5B), HNRNPC (Figure 5C), METTLE14 (Figure 5D), RBMX (Figure 5E), YTHDC1 (Figure 5F) expression has a significant impact on the poor prognosis of breast cancer patients. This suggests that M6A plays an essential role in breast cancer outcomes. We should note that Figure 5 shows the effect of high and low gene expression on OS in breast cancers where the expression of this gene was determined.

M6A regulators and clinical breast cancer parameters

We analyzed 6 genes, among which, compared with normal genes, *HNRNPA2B1* (Figure 6A) and *HNRNPC* (Figure 6B) were upregulated, *YTHDC1* (Figure 6C) and *METTLE14* (Figure 6D) were down-regulated, and *CBLL1* (Figure 6E) and *RMBX* (Figure 6F) showed no significant difference.

The differences in gene expression among Caucasian, Asian, and African American races, clinical stage, lymph node stage, and tumor subtypes were further analyzed. *HNRNPA2B1* was upregulated compared with normal expression in the race, stage 1-4, N0-N3, and tumor subtypes. It is noteworthy that the expression of N3 is relatively reduced compared with that of N0-N2. *HNRNPC* gene expression was higher than normal in all four comparisons. However, the expression of this gene is more significantly increased in African-American breast cancer patients and luminal breast cancer, and the expression of this gene is relatively decreased in stage 4 compared with stage 1-3, and it is also decreased in N3 compared with N0-N2.

By comparing the differences in the expression of YTHDC1 and METTLE14 in the three races, clinical stages, lymph node stages, and tumor subtypes, in each comparison, we found that all expressions were lower than in the normal sample, African Americans were significantly lower than in the other two groups of breast cancer patients, and the decline in stage 4 was greater than in the first three stages. The decrease of N3 expression was more obvious than that of N0-N2, and the decrease of triple-negative breast cancer was more obvious than that of the other two subtypes.

Among patients with abnormal *CBLL1* expression, only African-American breast cancer patients showed a statistically significant decrease in *CBLL1* expression compared with normal and the other two groups. Comparison with normal samples and groups showed that the expression of the *RBMX* gene was decreased in African-American breast cancer patients, decreased in stages 1 and 4, decreased in N3, and decreased in HER2-positive breast cancer, with statistical significance. In combination with Figure 5 and Figure 6, there is no significant difference in the expression of *CBLL1* and *RBMX* in breast cancer patients compared with normal patients in general. However, when these two genes are specifically expressed, higher gene expression is associated with poorer OS (Figure 6).

M6A regulator expression and immune infiltration in breast cancer

By reading relevant literature, we found that M6A is associated

with immunity in bladder cancer, oesophageal cancer and liver cancer. Therefore, we carried out GO and KEGG analysis with the hypothesis that M6A is associated with immunity in breast cancer, and found no KEGG result. The GO results are shown in the figure. Based on TIMER database, we examined the correlation between M6A regulators and the level of immune cell infiltration in breast cancer. The results are shown in Table 2. As shown in Figure 7, M6A regulators are associated with immune infiltration in breast cancer.

The relevance between M6A regulators expression and immuno regulators expression in breast cancer

To further explore the effects of M6A regulators on tumor immune response, we calculated the correlation between the expression of M6A regulators and immune regulators. As shown in Figure 8, The expression level of CBLL1, HNRNPA2B1, HNRNPC, METTLE14, RBMX, YTHDC1 were negatively correlated with Immunoinhibitors (Figure 8A), Immunostimulators (Figure 8B), and MHC molecules (Figure 8C) expressions in breast cancer (Figure 8).

GO and KEGG analysis

We implemented GO and KEGG enrichment analysis of CBLL1 (Figure 9A) HNRNPA2B1 (Figure 9B), HNRNPC (Figure 9C), METTL14 (Figure 9D), RBMX (Figure 9E), and YTHDC1 (Figure 9F) through Xian tao academic to explore the functional and enrichment analysis of these M6A regulators. The results showed that CBLL1 was remarkably related to nuclear speck, methyltransferase complex, methylation, macromolecule methylation, RNA modification, RNA methylation, mRNA modification, mRNA methylation, entry of bacterium into the host cell, and so on (Figure 9A). HNRNPA2B1 was significantly related to mRNA 3'-UTR binding, spliceosomal complex, RNA splicing, mRNA splicing, via spliceosome, RNA splicing, via transesterification reactions with bulged adenosine as a nucleophile, regulation of mRNA metabolic process, regulation of mRNA processing, regulation of RNA splicing, mRNA transport and so on (Figure 9B). HNRNPC was relevant to Spliceosome, mRNA 3'-UTR binding, RNA splicing, RNA splicing, via transesterification reactions, mRNA splicing, via spliceosome RNA splicing, via transesterification reactions with bulged adenosine as a nucleophile, regulation of mRNA metabolic process, and so on (Figure 9C). METTL14 was significantly correlated with RNA splicing, RNA splicing, via transesterification reactions, mRNA splicing, via spliceosome, regulation of mRNA metabolic process, methyltransferase complex, RNA modification, RNA methylation, positive regulation of mRNA metabolic process, mRNA modification, and so on (Figure 9D). RBMX was associated with RNA splicing, via transesterification reactions with bulged adenosine as a nucleophile, regulation of mRNA metabolic process, Spliceosome, Single-stranded RNA binding, mRNA 3'-UTR binding, G-rich strand telomeric DNA binding, spliceosomal complex, catalytic step 2 spliceosome, methyltransferase complex, and mRNA splicing, via spliceosome (Figure 9E). YTHDC1 was significantly related to RNA splicing, RNA splicing, via transesterification reactions, regulation of mRNA metabolic process, regulation of mRNA processing, regulation of RNA splicing, regulation of mRNA splicing, via spliceosome, mRNA export from the nucleus, and so on (Figure 9).

OPEN OACCESS Freely available online



Figure 5: Dysregulation of m6A is correlated with shorter OS times in breast cancer patients' higher levels. (A)CBLL1. HR=0.67(0.51-0.88), p=0.0034; (B)HNRNPA2B1. HR=0.69(0.52-0.9), p=0.0062; (C)HNRNPC. HR=0.69(0.52-0.9), p=0.0058; (D)METTL14. HR=0.69(0.53-0.9), p=0.0064; (E)RBMX. HR=0.59(0.45-0.77), p=0.00012; (F)YTHDC1. HR=0.78(0.65-0.95), p=0.012. Expression: () High; () Low.





Table 2: Examination of the correlation between M6Aregulators and the level of immune cell infiltration in breast cancer based on TIMER database.

	purity		B cell		CD8+ T cell		CD4+ T cell		Macrophage		Neutrophill		Dendritic cell	
Gene expression	partial cor	Р	partial cor	Р	partial cor	Р	Partial cor	Р						
CBLL1 (Figure 7A)	0.071	0.0251*	0.058	0.0689	0.284	1.27E-19***	0.108	0.000824***	0.196	5.18E-10***	0.16	7.04E-07	0.064	0.0409*
HNRNPA2B1 (Figure 7B)	0.203	1.11E-10***	0.169	1.01E-07***	0.14	1.22E-05***	0.152	2.22E-06 ***	0.038	0.236	0.173	8.32E-08***	0.135	2.87E-05 ***
HNRNPC (Figure 7C)	0.23	2.08E-13***	0.024	0.449	0.076	0.0172*	-0.02	0.527	0.038	0.228	0.006	0.847	-0.046	0.154
METTLE14 (Figure 7D)	0.032	0.312	0.043	0.18	0.324	2.87E-25***	0.101	0.00164**	0.292	8.14E-21***	0.201	3.66e-10***	0.095	3.30E-03 **
RBMX (Figure 7E)	0.146	3.48E-06***	0.009	0.788	0.244	1.09E-14***	0.122	0.000104**	0.063	0.0469*	0.137	2.27E-05***	0.038	0.238
YTHDC1 (Figure 7F)	0.087	0.00624**	0.031*	0.326	0.294	5.57E-21***	0.16	5.81E-07 ***	0.23	2.83E-13***	0.207	1.28E-10***	0.092	0.00474**

Note: *p<0.05; **p<0.01; ***p<0.0001.



Figure 8: Correlations between m6A regulators Expression and the expression of Immuno regulators in breast cancer. The correlations between the expression of CBLL1, HNRNPA2B1, HNRNPC, METTLE14, RBMX, YTHDC1. Note: (A) Immuno inhibitor; (B) Immuno stimulator; (C) MHC.



DISCUSSION

RNA molecules are an essential building block of all living organisms. These molecules act as carriers to transfer genetic information from DNA to proteins and as regulators of various biological processes [41]. RNA transcripts may undergo diverse and complex chemical modifications to tailor their structure to specific molecular functions. Indeed, more than a hundred posttranscriptional modifications have been found in cellular RNAs [42]. N6-methyladenosine (M6A) is considered to be the most abundant and most conserved internal modification in mRNA and long non-coding RNAs and is methylation of the nitrogen-6 position adenosine base [43]. N6-methyladenosine (M6A) modification was discovered and partially characterized in a great variety of cellular mRNAs in the 70s decade [44-45]. M6A represents the most abundant internal modification of eukaryotic mRNA and accounts for more than 80% of all RNA base methylations in various species. M6A mRNA methylation affects almost every stage of mRNA metabolism [46].

Research has shown that M6A methylation also regulates the expression of important genes and pathways that regulate cell fate, and dysregulation of these pathways by abnormal M6A methylation may lead to cancer for example, M6A regulates the PI3K/AKT pathway during T-cell development as well as in endometrial cancer, renal cell carcinoma, and AML [6,47-50]. In recent years, the role of the M6A regulator in breast cancer has been revealed in several previous studies. Such as aberrations of the M6A readers YTHDF1 and YTHDF3 are associated with metastasis in breast cancer patients and predict poor prognosis [51]. Altered genomic targets are associated with N6-methyladenosine in breast cancer tissue and associated with poor survival [52]. Similar results have been observed in breast cancer cells, where ALKBH5-mediated M6A demethylation of NANOG mRNA enhances Breast Cancer Stem Cells (BCSC) under hypoxia [53]. However, previous studies on the association between M6A methylation and breast cancer were mostly limited to a single molecule. Our study is the first to demonstrate that M6A regulators can be used as potential biomarkers for breast cancer prognosis and immunotherapy.

In this study, we systematically analyzed the expression of 23 M6A regulatory factors in breast cancer, and we found that abnormalities in the M6A regulatory factor in the genome are associated with breast cancer prognosis. In this study, we revealed that most M6A regulators are amplified, deleted, and mutated in breast cancer, with VIRMA having the highest incidence (11%). Virilizer Homolog (VIRMA) is also a key component of M6A methyltransferase and plays a role in the recruitment of core catalytic components METTL3, METTL14, and WTAP [54]. In TGCT, VIRMA and YTHDF3 may be prognostic factors [55]. At the same time, We found increased expression of six M6A regulators in breast cancer samples. Including VIRMA/KIAA1429, YTHDF1, HNRNPA2B1, HNRNPC, IGF2BP1, and IGF2BP3. However, the expression of METTLE14, METTL16, WTAP, FTO, ZC3H13, YTHDC1, IGF2BP3, ZCCHC4 was reduced to varying degrees compared with normal samples. Meanwhile, there was no difference in METTL3, ALKBH5, RBM15, RBM15B, YTHDF2, YTHDF3, YTHDC2, RBMX, CBLL1 expression between normal and tumor samples (Figure 4). We looked further and found that the high expression of CBLL1, HNRNPA2B1, HNRNPC, METTLE14, RBMX, and YTHDC1 had a significant impact on the poor prognosis of breast cancer patients (Figure 5), indicating these M6A regulators play important roles in breast cancer and hold the

key to the prognosis of patients. Previous studies have shown that in eukaryotes, proteins containing the YTH domain include five functional genes: YTHDF1, YTHDF2, YTHDF3, YTHDC1, and YTHDC2, which are distributed in the nucleus and cytoplasm. Proteins containing the YTH domain first recognize the M6A modification of the target RNA and then guide different complexes to regulate RNA signalling pathways, including RNA folding, RNA splicing, protein translation, and RNA metabolism [56]. Among proteins containing the YTH domain, YTHDC1 is the only one that is enriched in the nucleus. It regulates the splicing of mRNA by bridging the interaction between Trans and cis-regulatory elements and combining with targeted mRNA [57]. Studies have suggested that YTHDC1 may be differentially expressed in different tumors. For example, YTHDC1 is highly expressed in colorectal adenocarcinoma, but not in rectal adenocarcinoma [58]. In Gynaecologic tumor cell lines, RNA splicing is altered by decreased YTHDC1 protein levels due to hypoxia [59]. The evidence indicates that YTHDC1 is associated with prostate cancer [60]. METTL14 plays a vital role in the recognition of M6A methylated RNA substrates. Studies have shown that abnormal expression of METTL14 can alter the fate of M6A-regulated transcripts. METTL14 has been reported to alter M6A levels in HCC3 [61]. HnRNPA2B1, as an RNA-binding protein, accelerates the processing of pre-mRNA by forming a complex with lncRNA during the development of cancer. HNRNPA2B1 is involved in the development of pancreatic cancer, prostate cancer, hepatocellular carcinoma and lung cancer [62-65]. HCC patients with high cytoplasmic expression of hnRNPA2B1 showed a significantly higher incidence of low differentiation stage and lower survival rate than those with nuclear expression of hnRNPA2B1 [66-68]. In the study, increased RBMX expression was found to lead to poor prognosis in HCC patients [69].

The protection of harmful pathogens depends on the activation of the immune system, which relies on the strict regulation of gene expression. There is compelling evidence that M6A modification is particularly critical in a variety of pathological and physiological immune responses, including T cell homeostasis and differentiation, inflammation, and type I interferon production [70]. In this study, it was found that HNRNPA2B1, HNRNPC, YTHDC1, METTL14, CBLL1, RBMX were significantly correlated with the level of immune cell infiltration in breast cancer, as well as with the stromal score, estimate score, and immune score. Through the TISIDB database, we found that the three M6A regulators had a close connection with Immuno inhibitors, Immuno stimulators, and MHC molecules in breast cancer. It is also suggested that the occurrence of breast cancer is related to the immune disorder caused by the abnormal expression of M6A. In addition, external factors, including Tumor-Infiltrating Lymphocytes (TIL), can lead to tumor resistance to immunotherapy, Tumor-Associated Macrophages (TAM), and Myeloid Suppressor Cells (MDSC). To deepen the understanding of the tumor immune microenvironment. For example, PD-L1 expression, TIL, TAMs, and MDSC play an increasingly important role. In this study, we assessed the association between M6A and levels of immune cell infiltration in TISIDB tumors. We also performed a bioinformatics analysis of M6A in breast cancer.

Several limitations should be noted in this study. First, TCGA data were used for survival analysis. Validation of mRNA and protein levels in surgical samples from breast cancer patients further supports the work of M6A modulators as viable clinical biomarkers. Finally, the function of the M6A regulatory factor in breast cancer

will be further explored through functional loss analysis.

CONCLUSION

In conclusion, our study confirmed the dysregulation of tumorassociated M6A regulatory factor through bioinformatics analysis, which is associated with the prognosis of breast cancer patients and therefore can be used as a prognostic biomarker. In addition, we found that the expression of the M6A regulatory factor was associated with the level of immune invasion and the expression of immune regulatory factors in breast cancer. Our study suggests that M6A regulators may play a role as putative drug targets in breast cancer.

ETHICS APPROVAL AND CONSENT TO PARTICIPATE

This study was approved by the Medical Ethics Committee of Cancer Hospital affiliated with Xinjiang Medical University. Our study was conducted according to the ethical standards of the Declaration of Helsinki.

CONSENT FOR PUBLICATION

All the authors approved the publication of the manuscript.

AVAILABILITY OF DATA AND MATERIAL

The authors thank the TCGA, GEO, and *TISIDB* databases for the availability of the data and data analysis of the Xian Tao academic website.

COMPETING INTERESTS

There is no conflict of interest.

FUNDING

This study was funded by Natural Science Foundation of Xinjiang Uygur Autonomous Region [Project No: 2021D01C410].

AUTHORS' CONTRIBUTIONS

Yongtao Li and Muhairemu.Tuersuntuoheti designed this study, Yongtao Li and Muhairemu. Tuersuntuoheti Jianghua Ou, wrote and edited the manuscript, Xiaofang Chen and Xuelaiti. Paizula Lina Yi, reviewed and helped to analyze the data, and all authors read and approved the manuscript.

ACKNOWLEDGEMENTS

The authors thank the TCGA, GEO and *TISIDB* database for the availability of the data and data analysis of xian tao academic website.

REFERENCES

- Siegel RL, Miller KD, Goding Sauer A, Fedewa SA, Butterly LF, Anderson JC, et al. Cancer statistics. CA: Cancer J. 2020;70(3):07-70.
- Yang XR, Chang-Claude J, Goode EL, Couch FJ, Nevanlinna H, Milne RL, et al. Associations of breast cancer risk factors with tumor subtypes: A pooled analysis from the breast cancer association consortium studies. J Natl Cancer Inst. 2011;103(3):250-263.
- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality

- Muntean AG, Hess JL. Epigenetic dysregulation in cancer. Am J Pathol. 2009;175(4):1353-1361.
- He C. Grand challenge commentary: RNA epigenetics? Nat Chem Biol. 2010;6(12):863-865.
- 6. He L, Li H, Wu A, Peng Y, Shu G, Yin G. Functions of N6-methyladenosine and its role in cancer. Mol Cancer Res. 2019;18(1):1-5.
- 7. Roignant JY, Soller M. M6A in mRNA: An ancient mechanism for finetuning gene expression. Trends Genet. 2017;33(6):380-390.
- Engel M, Eggert C, Kaplick PM, Eder M, Röh S, Tietze L, et al. The role of M6A/m-RNA methylation in stress response regulation. Neuron. 2018;99(2):389:403.
- Beh LY, Debelouchina GT, Clay DM, Thompson RE, Lindblad KA, Hutton ER, et al. Identification of a DNA N6-adenine methyltransferase complex and its impact on chromatin organization. Cell. 2019;177(7):1781-1796.
- Ji L, Chen S, Gu L, Zhang X. Exploration of potential roles of M6A regulators in colorectal cancer prognosis. Front Oncol. 2020;10:768.
- Lu J, Qian J, Yin S, Zhou L, Zheng S, Zhang W. Mechanisms of RNA N6methyladenosine in hepatocellular carcinoma: From the perspectives of etiology. Front Oncol. 2020;10:1105.
- 12. Cui QI, Shi H, Ye P, Li L, Qu Q, Sun G, et al. M6A RNA methylation regulates the self-renewal and tumorigenesis of glioblastoma stem cells. Cell Rep. 2017;18(11):2622-2634.
- Yue H, Nie X, Yan Z, Weining S. N6-methyladenosine regulatory machinery in plants: Composition, function and evolution. Plant Biotechnol J. 2019;17(7):1194-1208.
- 14. Dai F, Wu Y, Lu Y, An C, Zheng X, Dai L, et al. Crosstalk between RNA M6A modification and non-coding RNA contributes to cancer growth and progression. Mol Ther Nucleic Acids. 2020;22:62-71.
- Zhang S, Zhao BS, Zhou A, Lin K, Zheng S, Lu Z, et al. M6A demethylase ALKBH5 maintains tumorigenicity of glioblastoma stem-like cells by sustaining FOXM1 expression and cell proliferation program. Cancer cell. 2017;31(4):591-606.
- Han J, Wang JZ, Yang X, Yu H, Zhou R, Lu HC, et al. METTL3 promote tumor proliferation of bladder cancer by accelerating pri-miR221/222 maturation in M6A-dependent manner. Mol. Cancer. 2019;18:1-5.
- Yang F, Jin H, Que B, Chao Y, Zhang H, Ying X, et al. Dynamic M6A mRNA methylation reveals the role of METTL3-M6A-CDCP1 signaling axis in chemical carcinogenesis. Oncogene. 2019;38(24):4755-4772.
- Ignatova VV, Kaiser S, Ho JS, Bing X, Stolz P, Tan YX, et al. METTL6 is a tRNA m3C methyltransferase that regulates pluripotency and tumor cell growth. Sci Adv. 2020;6(35):eaaz4551.
- Yi D, Wang R, Shi X, Xu L, Yilihamu YE, Sang J. METTL14 promotes the migration and invasion of breast cancer cells by modulating N6-methyladenosine and hsa-miR-146a-5p expression. Oncol Rep. 2020;43(5):1375-1386.
- Wu L, Wu D, Ning J, Liu W, Zhang D. Changes of N6-methyladenosine modulators promote breast cancer progression. BMC cancer. 2019;19:1-2.
- Qian JY, Gao J, Sun X, Cao MD, Shi L, Xia TS, et al. KIAA1429 acts as an oncogenic factor in breast cancer by regulating CDK1 in an N6methyladenosine-independent manner. Oncogene. 2019;38(33):612341.
- 22. Shahriyari L, Abdel-Rahman M, Cebulla C. *BAP1* expression is prognostic in breast and uveal melanoma but not colon cancer and is highly positively correlated with *RBM15B* and USP19. PLoS One. 2019;14(2):e0211507.
- 23. Gong EY, Park E, Lee K. Hakai acts as a coregulator of estrogen receptor alpha in breast cancer cells. Cancer Sci. 2010;101(9):2019-2025.
- 24. Niu Y, Lin Z, Wan A, Chen H, Liang H, Sun L, et al. RNA N6methyladenosine demethylase *FTO* promotes breast tumor progression through inhibiting *BNIP3*. Molecular cancer. 2019;18:1-6.
- 25. Liu Y, Wang R, Zhang L, Li J, Lou K, Shi B. The lipid metabolism gene

FTO influences breast cancer cell energy metabolism via the *PI3K/AKT* signaling pathway. Oncol Lett. 2017;13(6):4685-4690.

- 26. Zhang C, Zhi WI, Lu H, Samanta D, Chen I, Gabrielson E, et al. Hypoxiainducible factors regulate pluripotency factor expression by *ZNF217*-and *ALKBH5*-mediated modulation of RNA methylation in breast cancer cells. Oncotarget. 2016;7(40):64527.
- 27. Zhou Y, Meng X, Chen S, Li W, Li D, Singer R, et al. *IMP1* regulates UCA1-mediated cell invasion through facilitating UCA1 decay and decreasing the sponge effect of UCA1 for miR-122-5p. Breast Cancer Res. 2018;20:1-5.
- Kim HY, Thi HT, Hong S. *IMP2* and *IMP3* cooperate to promote the metastasis of triple-negative breast cancer through destabilization of progesterone receptor. Cancer lett. 2018;415:30-39.
- 29. Oliveira-Mateos C, Sánchez-Castillo A, Soler M, Obiols-Guardia A, Piñeyro D, Boque-Sastre R, et al. The transcribed pseudogene RPSAP52 enhances the oncofetal HMGA2-IGF2BP2-RAS axis through LIN28B-dependent and independent let-7 inhibition. Nat Commun. 2019;10(1):3979.
- Zhou Z, Zhou H, Ponzoni L, Luo A, Zhu R, He M, et al. *EIF3H* orchestrates Hippo pathway-mediated oncogenesis via catalytic control of YAP stability. Cancer Res. 2020;80(12):2550-2563.
- Sarbanes SL, Le Pen J, Rice CM. Friend and foe, HNRNPC takes on immunostimulatory RNA s in breast cancer cells. EMBO J. 2018;37(23):e100923.
- 32. Klinge CM, Piell KM, Tooley CS, Rouchka EC. *HNRNPA2/B1* is upregulated in endocrine-resistant *LCC9* breast cancer cells and alters the miRNA transcriptome when overexpressed in MCF-7 cells. Sci Rep. 2019;9(1):9430.
- 33. Liu Y, Li H, Liu F, Gao LB, Han R, Chen C, et al. Heterogeneous nuclear ribonucleoprotein A2/B1 is a negative regulator of human breast cancer metastasis by maintaining the balance of multiple genes and pathways. EBioMedicine. 2020;51.
- 34. Liu S, Li G, Li Q, Zhang Q, Zhuo L, Chen X, et al. The roles and mechanisms of YTH domain-containing proteins in cancer development and progression. Am J Cancer Res. 2020;10(4):1068.
- 35. Zhao H, Xu Y, Xie Y, Zhang L, Gao M, Li S, et al. M6A regulators is differently expressed and correlated with immune response of esophageal cancer. Front Cell Dev Biol. 2021;9:650023.
- 36. Chen M, Wei L, Law CT, Tsang FH, Shen J, Cheng CL, et al. RNA N6-methyladenosine methyltransferase-like 3 promotes liver cancer progression through YTHDF2-dependent posttranscriptional silencing of SOCS2. Hepatol. 2018;67(6):2254-2270.
- Dominissini D, Moshitch-Moshkovitz S, Schwartz S, Salmon-Divon M, Ungar L, Osenberg S, et al. Topology of the human and mouse M6A RNA methylomes revealed by M6A-seq. Nature. 2012;485(7397):201-206.
- Zaccara S, Ries RJ, Jaffrey SR. Reading, writing and erasing mRNA methylation. Nat Rev Mol. 2019;20(10):608-624.
- Zhang B, Gu Y, Jiang G. Expression and prognostic characteristics of m6 A RNA methylation regulators in breast cancer. Front Genet. 2020;11:604597.
- 40. Chandrashekar DS, Bashel B, Balasubramanya SA, Creighton CJ, Ponce-Rodriguez I, Chakravarthi BV, et al. UALCAN: A portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia. 2017;19(8):649-658.
- 41. Li T, Fan J, Wang B, Traugh N, Chen Q, Liu JS, et al. TIMER: A web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. 2017;77(21):e108-110.
- 42. Ru B, Wong CN, Tong Y, Zhong JY, Zhong SS, Wu WC, et al. *TISIDB*: An integrated repository portal for tumor–immune system interactions. J Bioinform. 2019;35(20):4200-4202.
- Liu N, Pan T. N 6-methyladenosine-encoded epitranscriptomics. Nat Struct Mol Biol. 2016;23(2):98-102.
- 44. Fu Y, Dominissini D, Rechavi G, He C. Gene expression regulation mediated through reversible M6A RNA methylation. Nat Rev Genet. 2014;15(5):293-306.

- 45. Salk JJ, Schmitt MW, Loeb LA. Enhancing the accuracy of next-generation sequencing for detecting rare and subclonal mutations. Nat Rev Genet. 2018;19(5):269-285.
- 46. Roy S, Kumar V, Bossier P, Norouzitallab P, Vanrompay D. Phloroglucinol treatment induces transgenerational epigenetic inherited resistance against Vibrio infections and thermal stress in a brine shrimp (Artemia franciscana) model. Front immunol. 2019;10:2745.
- Desrosiers R, Friderici K, Rottman F. Identification of methylated nucleosides in messenger RNA from Novikoff hepatoma cells. Proc Natl Acad Sci. 1974;71(10):3971-3975.
- SCHÄFER KP. RNA synthesis and processing reactions in a subcellular system from mouse L cells. 1982: 33-44
- 49. Bokar JA, Rath-Shambaugh ME, Ludwiczak R, Narayan P, Rottman F. Characterization and partial purification of mRNA N6-adenosine methyltransferase from HeLa cell nuclei. Internal mRNA methylation requires a multisubunit complex. J Biol Chem. 1994;269(26):17697-17704.
- Ma Z, Ji J. N6-methyladenosine (M6A) RNA modification in cancer stem cells. Stem Cells. 2020;38(12):1511-1519.
- 51. Lin X, Chai G, Wu Y, Li J, Chen F, Liu J, et al. RNA M6A methylation regulates the epithelial mesenchymal transition of cancer cells and translation of Snail. Nat Commun. 2019;10(1):2065.
- 52. Li HB, Tong J, Zhu S, Batista PJ, Duffy EE, Zhao J, et al. M6A mRNA methylation controls T cell homeostasis by targeting the *IL-7/STAT5/* SOCS pathways. Nature. 2017;548(7667):338-342.
- 53. Vu LP, Pickering BF, Cheng Y, Zaccara S, Nguyen D, Minuesa G, et al. The N 6-methyladenosine (M6A)-forming enzyme METTL3 controls myeloid differentiation of normal hematopoietic and leukemia cells. Nat Med. 2017;23(11):1369-1276.
- 54. Anita R, Paramasivam A, Priyadharsini JV, Chitra S. The M6A readers YTHDF1 and YTHDF3 aberrations associated with metastasis and predict poor prognosis in breast cancer patients. Am J Cancer Res. 2020;10(8):2546.
- 55. Liu L, Liu X, Dong Z, Li J, Yu Y, Chen X, et al. N6-methyladenosinerelated genomic targets are altered in breast cancer tissue and associated with poor survival. J Cancer.2019;10(22):5447.
- Uddin MB, Wang Z, Yang C. Dysregulations of functional RNA modifications in cancer, cancer stemness and cancer therapeutics. Theranostics. 2020;10(7):3164.
- 57. Elman JS, Ni TK, Mengwasser KE, Jin D, Wronski A, Elledge SJ, et al. Identification of *FUBP1* as a long tail cancer driver and widespread regulator of tumor suppressor and oncogene alternative splicing. Cell rep. 2019;28(13):3435-3449.
- 58. Lobo J, Costa AL, Cantante M, Guimarães R, Lopes P, Antunes L, et al. M6 A RNA modification and its writer/reader VIRMA/YTHDF3 in testicular germ cell tumors: A role in seminoma phenotype maintenance. Journal of translational medicine. 2019;17:1-3.
- Liao S, Sun H, Xu C. YTH domain: A family of N6-methyladenosine (M6A) readers. Genomics, proteomics & bioinformatics. 2018;16(2):99-107.
- Xiao W, Adhikari S, Dahal U, Chen YS, Hao YJ, Sun BF, et al. Nuclear M6A reader YTHDC1 regulates mRNA splicing. Mol Cell. 2016;61(4):507-519.
- Liu X, Liu L, Dong Z, Li J, Yu Y, Chen X, et al. Expression patterns and prognostic value of M6A-related genes in colorectal cancer. Am J Transl Res. 2019;11(7):3972.
- 62. Wu X, Sang L, Gong Y. N6-methyladenine RNA modification and cancers. Am J Cancer Res. 2018;8(10):1957.
- 63. Luxton HJ, Simpson BS, Mills IG, Brindle NR, Ahmed Z, Stavrinides V, et al. The oncogene metadherin interacts with the known splicing proteins YTHDC1, Sam68 and TSTAR and plays a novel role in alternative mRNA splicing. Cancers. 2019;11(9):1233.
- 64. Du C, Lv Z, Cao L, Ding C, Gyabaah OA, Xie H, et al. Mi*R*-1263*p* suppresses tumor metastasis and angiogenesis of hepatocellular carcinoma by targeting *LRP6* and *PIK3R2*. J Transl Med. 2014;12(1):1-1.

OPEN OACCESS Freely available online

- 65. Siveke JT. The increasing diversity of KRAS signaling in pancreatic cancer. Gastroenterology. 2014;147(4):736-9.
- 66. Stockley J, Villasevil ME, Nixon C, Ahmad I, Leung HY, Rajan P. The RNA-binding protein hnRNPA2 regulates β-catenin protein expression and is overexpressed in prostate cancer. RNA Biol. 2014;11(6):755-765.
- 67. Shilo A, Hur VB, Denichenko P, Stein I, Pikarsky E, Rauch J, et al. Splicing factor *hnRNPA2* activates the *Ras-MAPKERK* pathway by controlling A-Raf splicing in hepatocellular carcinoma development. Rna. 2014;20(4):505-515.
- 68. Tauler J, Zudaire E, Liu H, Shih J, Mulshine JL. *hnRNP* A2/B1 modulates epithelial-mesenchymal transition in lung cancer cell lines. Cancer Res. 2010;70(18):7137-7147.
- 69. Zhou ZJ, Dai Z, Zhou SL, Hu ZQ, Chen Q, Zhao YM, et al. *HNRNPAB* induces epithelial-mesenchymal transition and promotes metastasis of hepatocellular carcinoma by transcriptionally activating SNAIL. Cancer Res. 2014 May 15;74(10):2750-2762.
- 70. Song Y, He S, Ma X, Zhang M, Zhuang J, Wang G, et al. RBMX contributes to hepatocellular carcinoma progression and sorafenib resistance by specifically binding and stabilizing BLACAT1. Am J Cancer Res. 2020;10(11):3644.